This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts See a 33.95% Upside in Gitlab (GTLB): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 34% in Gitlab (GTLB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
After Plunging -18.51% in 4 Weeks, Here's Why the Trend Might Reverse for Gitlab (GTLB)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Gitlab (GTLB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks Industry Outlook Highlights Datadog, monday.com and Gitlab
by Zacks Equity Research
Datadog, monday.com and Gitlab have been highlighted in this Industry Outlook article.
3 Internet Software Stocks to Buy From a Prospering Industry
by Aniruddha Ganguly
The Zacks Internet software industry participants like Datadog (DDOG), monday.com (MNDY) and Gitlab (GTLB) are benefiting from high demand for SaaS due to the increasing need for remote working, learning, and diagnosis software, as well as cybersecurity applications.
Netflix and CVS Health have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Netflix and CVS Health have been highlighted as Zacks Bull and Bear of the Day
Does GitLab's (GTLB) Growing Clientele Make the Stock a Buy?
by Aniruddha Ganguly
GitLab (GTLB) is benefiting from an expanding clientele, driven by the strong adoption of its DevSecOps platform and a robust partner base.
Gitlab (GTLB) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Gitlab (GTLB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here's Why Gitlab (GTLB) is Poised for a Turnaround After Losing -16.61% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Gitlab (GTLB) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Do Options Traders Know Something About GitLab (GTLB) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to GitLab (GTLB) stock based on the movements in the options market lately.
GitLab (GTLB) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
GitLab's (GTLB) first-quarter fiscal 2025 results benefit from solid subscription revenue growth driven by expanding clientele.
GitLab Inc. (GTLB) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Gitlab (GTLB) delivered earnings and revenue surprises of 175% and 2.13%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
PagerDuty (PD) Q1 Earnings Top Estimates
by Zacks Equity Research
PagerDuty (PD) delivered earnings and revenue surprises of 30.77% and 0.51%, respectively, for the quarter ended April 2024. Do the numbers hold clues to what lies ahead for the stock?
Gitlab (GTLB) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Gitlab's (GTLB) first-quarter fiscal 2025 results are likely to reflect the solid performance of the DevSecOps platform, driven by expanding clientele.
GitLab Inc. (GTLB) Stock Moves -0.97%: What You Should Know
by Zacks Equity Research
In the most recent trading session, GitLab Inc. (GTLB) closed at $52.94, indicating a -0.97% shift from the previous trading day.
GitLab Inc. (GTLB) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
GitLab Inc. (GTLB) concluded the recent trading session at $53.36, signifying a +1.7% move from its prior day's close.
GitLab Inc. (GTLB) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
The latest trading day saw GitLab Inc. (GTLB) settling at $56.38, representing a +0.53% change from its previous close.
GitLab Inc. (GTLB) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw GitLab Inc. (GTLB) settling at $52.56, representing a -1.78% change from its previous close.
Here's Why GitLab Inc. (GTLB) Fell More Than Broader Market
by Zacks Equity Research
In the latest trading session, GitLab Inc. (GTLB) closed at $57.07, marking a -1.79% move from the previous day.
GitLab (GTLB) Boosts Security Solutions With Oxeye Acquisition
by Zacks Equity Research
Gitlab (GTLB) boosts DevSecOps with the Oxeye acquisition, enhancing SAST capabilities for streamlined security.
GitLab (GTLB) Posts Gain in Q4, Beats Revenue Estimates
by Zacks Equity Research
GitLab's (GTLB) fiscal fourth-quarter results benefit from solid subscription revenue growth driven by expanding clientele.
GitLab (GTLB) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
GitLab's (GTLB) fourth-quarter fiscal 2024 results are likely to reflect the solid performance of the DevSecOps platform, driven by expanding clientele.
New Strong Buy Stocks for January 22nd
by Zacks Equity Research
POWL, GT, ZUO, GTLB and SNAP have been added to the Zacks Rank #1 (Strong Buy) List on January 22, 2023.
GitLab (GTLB) Expands AI Momentum With the Latest Duo Launch
by Zacks Equity Research
GitLab's (GTLB) Duo Pro, priced at $19 per user monthly, transforms code collaboration and bolsters security with AI-driven DevSecOps, set to launch in February 2024.
Top Stock Picks for Week of January 15, 2024
by Panel Of Zacks Experts
An Interesting Mid Cap Stock and a Small-Cap Provider of Cancer Genetics Diagnostics for Your Consideration.
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics
by Zacks Equity Research
DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics are part of the Zacks top Analyst Blog.